Effect of Saffron Extract Supplementation on Emotional Well-being Alterations

Inclusion Criteria: * Healthy volunteers (as determines by medical history and clinical examination); * Male or female between 18 and 50 years of age; * Body Mass Index (BMI) 18.5 ≤ BMI \< 30 kg/ m2; * Subject with subclinical symptoms of depressed mood, anxiety, fatigue and/or stress, as determined by the presence of at least 6 or more symptoms of moderate intensity among the 18 symptoms listed in the modified neurotoxicity scale (NRS). * Subject able and willing to participate to the study by complying with the protocol procedures as confirmed by his dated and signed informed consent form; * Person affiliated or benefiting from a social security scheme. Exclusion Criteria: * Psychiatric comorbidity determined with the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM5) or history of psychiatric illness; * Neurodegenerative pathology (Alzheimer's disease, Parkinson's disease, dementia); * Cardio-metabolic diseases (cardiovascular diseases, type 1 or 2 diabetes...); * Untreated or unstabilised hypertension; * Severe chronic diseases (cancer, severe chronic pain, HIV, hepatitis, kidney disease, autoimmune diseases, etc.); * Chronic inflammatory diseases (Crohn's disease, coeliac disease, rheumatoid arthritis, etc.); * Pathologies likely to act on the Hypothalamus-Pituitary-Adrenal (HPA) axis or the adrenal cortical metabolism (e.g.: Cushing syndrome); * Untreated and/or unstabilised thyroid diseases (hypo/hyperthyroidism, Graves' disease...); * Subjects treated during the previous 6 months or being currently treated with psychotropic drugs prescribed and/or recommended for anxiety, depression, sleep disorders and generally for any neurological or psychological type of manifestation. The same applies to: * Drugs likely to have direct or indirect effects on psychiatric symptoms, notably regular use of corticoids or steroidal anti-inflammatories (e.g. Betamethasone, Cortivazol, Dexamethasone, Methylprednisolone, Prednisolone, Prednisone, Tetracosactide, Triamcinolone, etc.); * Any drug treatment aimed at improving or maintaining cognitive functions (e.g. Aricept, Exelon, Reminyl, Ebixa etc.); * Food supplements during the last 3 months prior to participation in this study. * Personal or professional event with potential severe impact on the subject's emotional and/or psychological state within the last 8 weeks (e.g. but not limited to: change of job function/position, death of a family member, divorce, surgery, accident, etc.); * Use of antibiotic treatment (\<2 months); * Recent treatment with non-steroidal anti-inflammatory drugs (\<1 month); * Bariatric surgery; * Subject with asthma, allergies (allergic rhinitis, atopic dermatitis); * Any documented or suspected food allergy to any component of the study products. * Drug dependence (except tobacco); * Tobacco use of more than 20 cigarettes per day; * Consumption of large quantities of coffee, tea, chocolate (more than 5 cups of coffee or tea and more than 20 g of dark chocolate per day) or regular daily consumption of herbal infusions with relaxing or hypnotic properties \[e.g. chamomile, valerian, passionflower etc\]; * Alcohol abuse (maximum 2 drinks per day, maximum 10 drinks per week with several days of abstinence) or recreational drug use based on the participant's declaration; * Eating disorders: anorexia and bulimia or unstable diet; * Xerostomia or other conditions that may make saliva collection impossible; * Subjects working shifts or in extreme conditions (e.g. cold storage); * Intense physical activity: more than 10 hours per week of intense physical activity, or significant change in physical activity within the last 2 months, or physical activity likely to be modified within the next 6 weeks. Examples of moderate to vigorous physical activity are: carrying heavy loads, playing tennis (singles or doubles), combat sports, "fast" swimming, jogging etc. Walking is not considered a moderate intensity physical activity. * Subjects whose language skills do not allow them to understand the questionnaires; * Disability (psychological, visual, psychomotor, linguistic...) likely to compromise to understand and sign the consent form and to complete self-questionnaires during the study. * Subject participating in another interventional study or being in the exclusion period of a previous clinical trial; * Subject receiving more than 4500 euros as indemnities for participation in biomedical research within the 12 last months, including indemnities for the present study; * Women who are pregnant, intend to become pregnant during the study or are breastfeeding. * Hormonal state that may induce a fluctuating emotional state during the study, such as, postpartum (\< 6 months after delivery) and peri-menopause (irregular menstrual cycle, hot flashes, feeling of swelling, breast tension). * Subjects under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;